Euro vs US Dollar

Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.

Registrieren

ABBV AbbVie Inc

188,86

0,29 (0,15%)

19 Okt 2024 - Geschlossen

Verzögert um 15 Minuten

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Article too big to display. Click here to view on the SEC website

AbbVie (NYSE:ABBV)
Historical Stock Chart
Von Sep 2024 bis Okt 2024

Click Here for more AbbVie Charts.

AbbVie (NYSE:ABBV)
Historical Stock Chart
Von Okt 2023 bis Okt 2024

Click Here for more AbbVie Charts.

News AbbVie Inc

BOTOX® Cosmetic (onabotulinumtoxinA) Receives FDA Approval for Moderate to Severe Vertical Bands Connecting the Jaw and Neck (Platysma Bands)
Samstag 19 Oktober 2024 (1 Tag vor) • PR Newswire (US)

U.S. FDA Approves VYALEV™ (foscarbidopa and foslevodopa) for Adults Living with Advanced Parkinson's Disease
Donnerstag 17 Oktober 2024 (3 Tage vor) • PR Newswire (US)

Allergan Aesthetics to Present New Data at 2024 American Society for Dermatologic Surgery (ASDS) to Showcase Depth Across Facial Aesthetics and Insight into Patient Perception
Mittwoch 16 Oktober 2024 (4 Tage vor) • PR Newswire (US)

Allergan Aesthetics and Girls Inc. Celebrate Six Years and Challenge You to Take the Pledge to Support Mentorship in STEM
Freitag 4 Oktober 2024 (2 Wochen vor) • PR Newswire (US)

Form 8-K - Current report
Donnerstag 3 Oktober 2024 (2 Wochen vor) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Mittwoch 2 Oktober 2024 (2 Wochen vor) • Edgar (US Regulatory)

Transforming Alzheimer's Treatment: Innovative Combinations to Boost Cognition
Mittwoch 2 Oktober 2024 (3 Wochen vor) • InvestorsHub NewsWire

Available Nationwide: JUVÉDERM® VOLUMA® XC for Moderate to Severe Temple Hollowing
Mittwoch 2 Oktober 2024 (3 Wochen vor) • PR Newswire (US)

AbbVie to Host Third-Quarter 2024 Earnings Conference Call
Dienstag 1 Oktober 2024 (3 Wochen vor) • PR Newswire (US)

Form 4 - Statement of changes in beneficial ownership of securities
Montag 30 September 2024 (3 Wochen vor) • Edgar (US Regulatory)

AbbVie Submits Biologics License Application to the FDA for Telisotuzumab Vedotin (Teliso-V) in Previously Treated Non-Small Cell Lung Cancer
Freitag 27 September 2024 (3 Wochen vor) • PR Newswire (US)

AbbVie and SpinUp Foster Canadian Life Sciences Innovation with the Launch of the AbbVie Biotech Innovators Award
Donnerstag 26 September 2024 (3 Wochen vor) • PR Newswire (Canada)

Weitere AbbVie Inc News-Artikel

BNP Paribas (QX)

Euro vs US Dollar

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen